EATRIS works with public funding agencies, charities and policy makers with tailored actions to help improve the translational research ecosystem. EATRIS policy efforts include raising the awareness on the impact of Translational Research; supporting the European research ecosystems to facilitate responsible research policies and engage society in the research and innovation decision-making processes; facilitating the digital transformation in Europe to unlock the power of data to improve health and, making meaningful patient engagement in translational research the new normal.
Here are some of our notable advocacy efforts:
- September 2025: EATRIS provides feedback on the “EU cardiovascular health plan”. Read our feedback here.
- July 2025: EATRIS Joins Call for Urgent EU Action to Protect Clinical Research Ecosystem. Find out more here.
- July 2025: EATRIS submitted feedback to the European Commission’s call on the Gender Equality Strategy 2026–2030, highlighting key actions to improve gender equity in health and biomedical research. Read our feedback here.
- June 2025: EATRIS provides feedback on the EC consultation on the Biotech Act. Read the feedback here.
- June 2025: EATRIS provides feedback on the EC consultation on the European Strategy for AI in science. Read the feedback here.
- May 2025: EATRIS provides feedback on the EC consultation on the European strategy on research and technology infrastructures. Read the feedback here.
- April 2025: EATRIS provides a response to the Public Consultation on the EU Life Sciences Strategy to rapidly developing, translating and commercialising innovative ideas and solutions in the EU. Read our input here.
- March 2025: EATRIS is now officially registered with the Research Organisation Registry (ROR), a global, community-led registry providing open, persistent identifiers (PIDs) for research organisations. Our ROR entry enhances discoverability, ensures consistent attribution of research outputs, and facilitates seamless integration into scholarly infrastructure, strengthening EATRIS’s visibility across global translational medicine initiatives. Visit our ROR entry here to explore and reference EATRIS resources easily.
- March 2025: EATRIS has provided feedback on the “EU Start-up and Scale-up Strategy”, which outlines policy, financial, and legislative measures to enhance and streamline framework conditions for start-ups and scale-ups. Read our input here.
- March 2025: Together with 38 other European health organisations, EATRIS co-signs the European Health Data Space (EHDS) Multi-Stakeholder Statement, urging policymakers to ensure meaningful stakeholder engagement and capacity building during EHDS implementation. The statement advocates for an inclusive, actionable process in shaping this new health data ecosystem. Read the joint statement here.
- February 2025: EATRIS provides a response to the Public Consultation on the “Critical Medicines Act” that addresses supply chain vulnerabilities of critical medicines and reduces Europe’s dependencies to strengthen the supply of critical medicines. More details here.
- December 2024: EATRIS provides response to the EMA consultation on an European Platform for Regulatory Science Research.
- December 2024: EATRIS provides response to the EMA consultation on “Regulatory Science Research Needs” 2024 Update.
- November 2024: EATRIS Expert Centers provide feedback on the draft implementing act for the joint scientific consultations (JSC) on medical devices (MDs) and in vitro diagnostic medical devices (IVDs). View the feedback from EATRIS-ERIC here.
- October 2024: EATRIS provides feedback to the Multi-Stakeholder Platform Advisory Group on proposals for EU-level funding to support academic sponsors conduct multi-national clinical trials.
- October 2024: EATRIS co-authors a strategic vision for European Life Science Research Infrastructures in Framework Programme 10 (More details here)
- August 2024: EATRIS answers to the Multi-stakeholder Consultation on FUTURE-PROOF AI ACT: TRUSTWORTHY GENERAL-PURPOSE AI
- July 2024: EATRIS joins the EU Transparency Register (More details here)
- July 2024: EATRIS Joins EU Health Policy Platform’s Thematic Network on AI-powered Imaging for Cancer Care (More here details here)
- February 2024: EATRIS is signatory of the press release “The draft text of the European Health Data Space (EHDS in trilogues sparks deep concerns in the European Healthcare ecosystem”
- November 2023: Short Statement from EATRIS on the “Revision of the EU general pharmaceuticals legislation”. More details here.
- December 2022: The ‘Rare Disease Moonshot’ launches, with EATRIS as a partner since its conception. More details here.
- July 2022: EATRIS’ reaction to the European Commission’s proposal for a Regulation on the European Health Data Space. More details here.
- May 2021: Porto Declaration on Cancer Research: EU-AMRI calls for further deployment of high-quality infrastructures. More details here.
- October 2020: “European Medical Research Infrastructures Call for Global Coordination” published in Clinical Infectious Diseases journal. More details here.
- September 2020: EATRIS, ECRIN, BBMRI and ELIXIR publish a joint statement on the Horizon Europe Cancer Mission. More details here.
- May 2020: COVID-19 Pandemic Readiness: European Medical Research Infrastructures are part of the global response. This statement included five practical steps to accelerate COVID-19 research and was published on Euractiv.com. More details here and view on Euractiv.com here.
- September 2018: Medical ERIC’s release a joint statement on Horizon Europe. More details here.
Main EU legislative proposals or policies targeted:
- AI Act
- EU general pharmaceuticals legislation
- EU Data Protection Regulation
- EU Health Data Space
- Implementation of the new In vitro diagnostics regulation and medical devices regulation
- Horizon Europe, EIC, EU4Health
- ERIC regulation
List of membership in associations, networks and other bodies:
EATRIS established partnerships with other research infrastructures and e-infrastructure providers to ensure that its researchers have access to the resources they need. EATRIS is an active member of EU-AMRI – a collaboration across three Life Science Research Infrastructure EATRIS, BBMRI, and ECRIN. EATRIS is an observer of the EOSC Association, an active contributor to the EOSC development.
EATRIS is a member of the Personalised Medicine Coalition (PMC) and the Federation of European Academies of Medicine (FEAM).
EATRIS is a partner of the EU Health Coalition and a member of the Coalition for Advancing Research Assessment (CoARA).
EATRIS is a permanent representative in the ACT EU Multi-stakeholder Platform Advisory Group.
